SCHEMBL2060404

SCHEMBL2060404

Nc1ccc2c(c1)C(=O)NCCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.67
MAPKAPK2 P49137 2/20 0.46
GAA P10253 3/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 1/20 0.40
GSK3B P49841 1/20 0.39
LMNA P02545 1/20 0.38
JAK2 O60674 4/20 0.37
NTRK1 P04629 4/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
BRD4 O60885 1/20 0.36
PARP1 P09874 1/20 0.36
JAK3 P52333 3/20 0.35
ROS1 P08922 2/20 0.35
JAK1 P23458 2/20 0.35
ALK Q9UM73 2/20 0.35
PLK4 O00444 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384774 1.00 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTKDM4E
SCHEMBL2061574 0.87 FABP6 (0.54) FABP6MAPKAPK2GAAMAPTKDM4E
SCHEMBL29783371 0.80 FABP6 (1.00) FABP6JAK2NTRK1PARP1JAK3
SCHEMBL22131596 0.80 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTKDM4E
SCHEMBL2062754 0.80 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTKDM4E
SCHEMBL886670 0.80 FABP6 (1.00) FABP6JAK2NTRK1PARP1JAK3
SCHEMBL2983127 0.80 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTALDH1A1
SCHEMBL3125131 0.80 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTALDH1A1
SCHEMBL31597716 0.80 FABP6 (0.67) FABP6MAPKAPK2GAAMAPTALDH1A1
SCHEMBL16976375 0.79 FABP6 (0.65) FABP6MAPKAPK2GAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114057716-B Benzazepinones and salts thereof, preparation method and medical application thereof 承德医学院 2023-06-09 CN disclosed
CN-114057716-A Benzazepinone compound and salt thereof, preparation method and medical application thereof 承德医学院 2022-02-18 CN disclosed
US-9868735-B2 Benzazepine ketone compounds as glycogen phosphorylase inhibitor, preparation method therefor, and medical uses CHENGDE MEDICAL UNIVERSITY (CN) 2018-01-16 US disclosed
EP-2684874-B1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors CEPHALON INC (US) 2017-05-17 EP disclosed
EP-2684874-B1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors CEPHALON INC (US) 2017-05-17 EP disclosed
US-20160229848-A1 Benzazepine Ketone Compounds as Glycogen Phosphorylase Inhibitor, Preparation Method therefor, and Medical Uses CHENGDE MEDICAL UNIVERSITY (CN) 2016-08-11 US disclosed
EP-2222647-B1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2015-08-05 EP disclosed
EP-2222647-B1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2015-08-05 EP disclosed
EP-2684874-A1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors Cephalon, Inc. (US) 2014-01-15 EP disclosed
EP-2684874-A1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors Cephalon, Inc. (US) 2014-01-15 EP disclosed
US-8148391-B2 Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors CEPHALON, INC. (US) 2012-04-03 US disclosed
EP-2222647-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS Cephalon, Inc. (US) 2010-09-01 EP disclosed
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS CEPHALON, INC. (US) 2009-09-03 US disclosed
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS CEPHALON, INC. (US) 2009-09-03 US disclosed
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS CEPHALON, INC. (US) 2009-09-03 US disclosed
WO-2008051547-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2008-05-02 WO disclosed
EP-0355598-B1 BETA-PHENOXYETHYL AMINES AND THEIR USE IN THE PREPARATION OF DYES BAYER AG (DE) 1993-06-16 EP disclosed
US-5126481-A Cyclization, reduction, decyclization BAYER AKTIENGESELLSCHAFT (DE) 1992-06-30 US disclosed
US-5041629-A Beta-phenoxyethylamines and their use for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1991-08-20 US disclosed
EP-0355598-A2 Beta-phenoxyethyl amines and their use in the preparation of dyes BAYER AG (DE) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221555-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS ALK, MET, RET FABP6 3064/4885MAPKAPK2 592/4885GAA 3538/4885
US-20160229848-A1 Benzazepine Ketone Compounds as Glycogen Phosphorylase Inhibitor, Preparation Method therefor, and Medical Uses PYGB, PYGL, AGL FABP6 2131/4885MAPKAPK2 983/4885GAA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.